Episode 12: Innovation & Risk in Pharma - Dr. John Hubbard, Strategic Healthcare Advisor, Board Member and Chairman

In this warm, wide-ranging conversation, Dr. John Hubbard, Strategic Healthcare Advisor, Board Member, and former CEO and President of multiple organizations across pharma and CROs, sits down with longtime friend Patty to reflect on a career that has spanned nearly every side of drug development: bench science, big pharma, a fast-growing CRO, and a private equity-backed technology company. A self-described “border collie” who never likes to rest on his laurels, John shares how a mentor’s regular nudge to keep moving shaped his remarkable path. 

You’ll hear John and Patty explore how industry collaboration opened up critical conversations about quality, what it takes to lead a large-scale transformation, and how the CRO industry has evolved since its earliest days. They also dig into the tension between innovation and risk aversion, why so many good ideas stall, and the mindset that helps leaders weather the inevitable setbacks. This episode explores what it takes to build strong foundations and still move boldly in a cautious industry. 

What you’ll hear about 

• How does quality shape the ability to accelerate clinical development? 

• What happens when competitors share lessons learned instead of guarding them? 

• Which outsourcing model works best: full service, FSP, or hybrid? 

• Why is it harder for large CROs to make bold moves today? 

• Why do so many innovations get stuck in endless pilot mode? 

• What traits help leaders stay steady when clinical trials go wrong? 

This episode is intended for clinical development operations and outsourcing leaders, offering a clear perspective on building quality into partnerships and moving innovation from pilot to practice. 

Timestamps 

00:50 – Punching above its weight: the early days of ICON 

02:50 – From bench scientist to big pharma leader 

07:05 – When quality data sparks a call to action 

12:00 – Why quality shouldn’t be a competitive secret 

13:40 – Taking the leap to a PE-backed company 

19:10 – A restless mind and an early love of research 

22:50 – Leadership lineage and the toughest turnaround 

25:55 – How the CRO industry grew up 

28:45 – FSP, full service, or hybrid? 

31:10 – Can big CROs still make bold moves? 

34:45 – Innovation vs. risk aversion 

37:55 – Escaping pilot hell 

40:15 – Adventures from Botswana to Tahiti 

44:25 – A leader’s superpower 

Guest Biography 

Dr. John Hubbard is a Strategic Healthcare Advisor, Board Member, and former CEO and President of multiple organizations across pharma and CROs, bringing more than 35 years of experience across drug discovery, big pharma, CROs, and clinical technology. After starting out as a bench scientist, he helped grow ICON into a top-tier CRO, led development operations at Pfizer through a major transformation, and served as CEO of Bioclinica, while also helping launch industry collaborations such as TransCelerate. Today, he is devoted to mentoring the next generation of leaders and championing a strong quality foundation across the industry.